In a recent turn of legal events, the concept of tort law is being examined for possible expansion. In particular, California’s Court of Appeal is deliberating a case that could notably alter liability under California tort law for pharma companies and all those deemed innovators. The case in question is Gilead v. Superior Court, (No. A165558).
Interestingly, the oral arguments witnessed shed light on whether a prescription drug manufacturer can be held liable under tort not due to a product defect, but rather negligence in failing to develop an allegedly safer product sooner. As told by the legal experts at Reed Smith.
As the circumstances of the case come under further scrutiny, legal professionals worldwide are anticipating it could prompt an evolution in tort law. Should the court rule in favor of the plaintiff, it would establish a new precedent, suggesting that a company’s duty of care extends to innovation – and the timely delivery of it – in addition to the product’s safety and functionality.
This potential shift could have significant implications for numerous sectors. Clearly, pharmaceutical companies are at the heart of this case. However, the ripple effects could extend to all entities identified as “innovators.” It may spur or even demand them to accelerate their product development and innovation initiatives, lest they fall foul of the newly interpreted “duty to innovate”.
At this stage, the outcome of Gilead v. Superior Court remains uncertain. However, legal professionals, innovators, and stakeholders are keeping a close eye on the developments. Should this case establish a novel expansion of tort law, it not only affects potential liability but also might reshape the pace and trajectory of innovation to meet the new ‘duty’ requirement.